Precision Medicine: Strategic Intelligence
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Precision and personalized medicine is transforming the global healthcare landscape by shifting treatment approaches from generalized protocols to patient-specific care models. By tailoring medical treatments based on genetic makeup, lifestyle, and environmental factors, precision medicine enables more accurate diagnoses, targeted therapies, and improved patient outcomes. This evolution represents a fundamental move away from traditional healthcare models toward data-driven, individualized care.
The growing integration of big data, bioinformatics, and artificial intelligence is accelerating this transition. Advanced analytics and genomic insights are enabling healthcare providers to predict disease risks, personalize treatment plans, and improve clinical decision-making. As healthcare systems increasingly rely on digital and genomic intelligence, precision medicine is becoming central to modern diagnostics, drug development, and care delivery.
Innovation across enabling technologies is further expanding the precision medicine ecosystem. Genomics, personal health data, AI-enabled tools, wearables, digital twins, and 3D printing are reshaping how diseases are detected, monitored, and treated. These capabilities are particularly impactful in oncology, where targeted therapies, tumor genomics, liquid biopsies, and biomarker-driven screening are driving more personalized and effective treatment strategies.
As investment and adoption accelerate, precision and personalized medicine is emerging as a core strategic theme across pharmaceuticals, diagnostics, medtech, hospitals, and digital health. Its growing influence is redefining R&D priorities, clinical workflows, and healthcare outcomes worldwide.
Scope
- This report examines precision and personalized medicine as a strategic healthcare theme.
- It tracks how precision medicine technologies are transforming diagnostics, including molecular testing, companion diagnostics, and biomarker-driven screening.
- The analysis highlights advances in oncology, focusing on targeted therapies, tumor genomics, and liquid biopsy technologies.
- It examines macroeconomic forces, policy movements, reimbursement shifts, and regulatory frameworks shaping the global precision medicine landscape.
- The report provides in-depth coverage of enabling technologies such as genomics, AI, wearables, digital twins, personal health data, and 3D printing in healthcare.
How industry leaders are using this report
Healthcare and life sciences leaders use this report to:
- Guide R&D strategies for targeted drugs, biologics, gene therapies, and personalized treatment platforms.
- Prioritize oncology programs using insights into tumor genomics and biomarker-driven therapies.
- Refine molecular diagnostics and companion testing portfolios.
- Support the expansion of hospital precision care programs, including genomic testing and AI-enabled workflows.
- Identify partnership and collaboration opportunities across genomics, bioinformatics, AI, and digital health.
- Navigate reimbursement, policy, and regulatory considerations affecting precision medicine adoption.
Key Highlights
This report explores the precision and personalized medicine theme, offering:
- A comprehensive review of the precision and personalized medicine value chain, covering genomics, personal health data, 3D printing, and other enabling technologies.
- Insight into emerging innovations such as multi-omics integration, AI-enabled clinical decision support, personalized cancer vaccines, and next-generation diagnostic platforms.
- Competitive landscape analysis profiling leading players across pharma, medtech, diagnostics, genomics, and data analytics.
Reasons to Buy
This report provides:
- Clear visibility into how precision and personalized medicine is reshaping healthcare delivery and innovation.
- Insights into leading companies and their positioning across the precision medicine value chain.
- Analysis of technology, macroeconomic, and regulatory trends influencing market adoption.
- A forward-looking view of growth opportunities across targeted therapies, diagnostics, and digital health.
- Strategic intelligence to support investment, partnership, and long-term planning decisions.
Who should buy this report
This report is designed for stakeholders seeking a strategic view of precision and personalized medicine, including:
- Pharma and Biopharma Companies
- Diagnostics and Genomics Companies
- Medical Device and MedTech Innovators
- Hospitals, Healthcare Providers, and Integrated Delivery Networks
- Health Tech, AI, and Data Analytics Firms
- Payers and Healthcare Policymakers
- Investors and Consultants
Illumina
Roche
10x Genomics
Siemens
Thermo Fisher Scientific
Materialise
Stryker
Danaher
Sophia Genetics
Guardant Health
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Medical Devices reports